GlaxoSmithKline, one of the world leaders in producing high-quality drugs is now one step closer in releasing their version of a cervical cancer vaccine.
According to federal regulators, the British drugmakers are on the right track in gaining approval of the U.S. health agency.
In a document released online, the Food and Drug Administration (FDA) said that the vaccine Cervarix, which is manufactured by Glaxo blocked two leading strains human papilloma virus or HPV, 93 percent of the time.
At the moment, the market for such vaccine in the U.S. is monopolize by Merck's super vaccine Gardasil, which is also offered not just to women but as well as to boys and men.
The agency will ask a panel of vaccine experts next week to weigh in on both vaccines. The FDA is not required to follow the group's advice, though it usually does.Yahoo! News reports.